Activation of TLR5 by flagellin has been shown to suppress cell proliferation and tumor growth in breast cancer cells, indicating that TLR5 may serve as a novel therapeutic target for human breast cancer therapy (15). This evidence concerns the gene TLR5 and neoplasm.